Difference between revisions of "Elafin (TG3)"
(New page: {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" ! {{infobox header}}| '''{{PAGENAME}}''' |- | align="center" colspan="2...) |
|||
| Line 39: | Line 39: | ||
|- | |- | ||
| Surface accessibility | | Surface accessibility | ||
| − | | [http://gibk21.bse.kyutech.ac.jp/asaview/all/ | + | | [http://gibk21.bse.kyutech.ac.jp/asaview/all/2rel.pdf ASAView] pdf |
| + | [http://gibk21.bse.kyutech.ac.jp/asaview/all/2rel.txt ASAView] txt | ||
|- | |- | ||
| Disorder prediction | | Disorder prediction | ||
Revision as of 11:25, 25 July 2007
| Template:Infobox header| Elafin (TG3) | |
|---|---|
| Elafin (TG3) | |
| Substrate peptide name | Elafin (TG3) |
| Synonyms | Cementoin
Elastase-specific inhibitor |
| Determination type | In situ/In vitro |
| Source | Homo sapiens |
| Subcellular localization | Cornified evelope |
| Swissprot ID | P19957 |
| Reactive glutamines | Q2 Q59 |
| Reactive lysines | K6 |
| Substrate sequence | AQEPVKGPV
ACFVPQ |
| Structure | 2REL |
| Surface accessibility | ASAView pdf
ASAView txt |
| Disorder prediction | IUPred |
| Reference | PMID:7543090 |
| Notes | |
| Template:Infobox header | | |
.png){kind=link}